Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Common Equity: 2009-2024

Historic Common Equity for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $403.7 million.

  • Ani Pharmaceuticals' Common Equity fell 0.99% to $505.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.8 million, marking a year-over-year decrease of 0.99%. This contributed to the annual value of $403.7 million for FY2024, which is 21.48% down from last year.
  • Ani Pharmaceuticals' Common Equity amounted to $403.7 million in FY2024, which was down 21.48% from $514.1 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Common Equity registered a high of $514.1 million during FY2023, and its lowest value of $214.4 million during FY2020.
  • Its 3-year average for Common Equity is $440.6 million, with a median of $403.9 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 80.94% in 2021, then fell by 21.48% in 2024.
  • Ani Pharmaceuticals' Common Equity (Yearly) stood at $214.4 million in 2020, then spiked by 80.94% to $387.8 million in 2021, then climbed by 4.14% to $403.9 million in 2022, then increased by 27.28% to $514.1 million in 2023, then declined by 21.48% to $403.7 million in 2024.